CXCL8 and metabolic dysfunction-associated steatohepatitis: Therefore, CXCL8 is likely associated with advanced stages of MASLD and may possibly serve as a non-invasive index to differentiate patients with advanced disease, i.e., those requiring pharmacotherapy, which has been more imperative since the introduction of resmetirom in the clinical management of patients with NASH [4].